Gene therapy for advanced geographic atrophy
Part of Eyes & vision clinical trials.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have geographic atrophy (an advanced form of dry age-related macular degeneration).
- Your vision in the eye to be treated is 20/200 or worse (but not completely blind), and your other eye is not significantly better.
- You have not had 'wet' (exudative) age-related macular degeneration in the eye to be treated.
- You have not had prior gene therapy.
- You are willing to use effective contraception, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study tests an oral medication called BRX011 taken once daily for geographic atrophy, a progressive form of advanced dry age-related macular degeneration. The goal is to see if it is safe and can help slow vision loss.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.